We have investigated the expression of COX-1, COX-2 and iNOS protein in human pancreas tissue in normal and pathological conditions. Tissue samples were obtained during surgery from patients with adenocarcinoma of pancreas from a nonnecrotic area of the tumour and control specimens from adjacent nontumorous tissue. The expression of COX-1, COX-2 and iNOS protein was evaluated by Western blot analysis. COX-2 was detected in all tumour samples. The levels of COX-2, determined by densitometry, were consistently higher in cancer tissue in comparison to paired control samples. On the contrary, the expression of COX-1 was weak in both control and cancerous specimens and the intensity of COX-1 was equivalent in all specimens. The expression of iNOS in cancer pancreas was greater than that of nontumour tissues where it was barely detectable. Overexpression of iNOS and COX-2 was demonstrated in all cancerous specimens, suggesting that both iNOS and COX-2 are involved in pancreatic cancer and can have important clinical implications. The iNOS and COX-2 may form the basis for a novel therapeutic approach such as pharmacological antagonism, or antisense gene therapy. This method could be utlized for different pathological condition of pancreas such as necrotizing or chronic pancreatitis.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 in human pancreas
BERTAZZONI MINELLI, Elisa;FRANCO, Luigina;DORIA, Denise;BENINI, Anna;BASSI, Claudio;SALVIA, Roberto;PEDERZOLI, Paolo
2001-01-01
Abstract
We have investigated the expression of COX-1, COX-2 and iNOS protein in human pancreas tissue in normal and pathological conditions. Tissue samples were obtained during surgery from patients with adenocarcinoma of pancreas from a nonnecrotic area of the tumour and control specimens from adjacent nontumorous tissue. The expression of COX-1, COX-2 and iNOS protein was evaluated by Western blot analysis. COX-2 was detected in all tumour samples. The levels of COX-2, determined by densitometry, were consistently higher in cancer tissue in comparison to paired control samples. On the contrary, the expression of COX-1 was weak in both control and cancerous specimens and the intensity of COX-1 was equivalent in all specimens. The expression of iNOS in cancer pancreas was greater than that of nontumour tissues where it was barely detectable. Overexpression of iNOS and COX-2 was demonstrated in all cancerous specimens, suggesting that both iNOS and COX-2 are involved in pancreatic cancer and can have important clinical implications. The iNOS and COX-2 may form the basis for a novel therapeutic approach such as pharmacological antagonism, or antisense gene therapy. This method could be utlized for different pathological condition of pancreas such as necrotizing or chronic pancreatitis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.